“…However, only 8% of the patients received PMRT in the SLNB arm compared to 27% in the ALND arm, which calls for an updating of the long-term outcomes in this population [ 19 ]. Three other prospective, randomized trials, whose results are pending, will soon shed light on this topic [ 20 , 21 , 22 ]. The SENOMAC trial, recently presented in an abstract form with some pre-specified secondary outcomes, investigated ALND omission in cT1-3N0 patients (whatever the surgery type) with up to two macrometastases after SLNB.…”